「dise」の検索結果

Selects spironolactone as first-line mineralocorticoid receptor antagonist for bilateral primary aldosteronism, with eplerenone as an alternative when spironolactone–related adverse effects are problematic. Trigger phrases include 'confirmed bilateral PA on AVS', 'idiopathic adrenal hyperplasia', 'bilateral adrenal hyperplasia', 'glucocorticoid-remediable aldosteronism', and 'initiating medical therapy for bilateral adrenal disease'.

日本語の概要は準備中です。原文の説明を表示しています。

Determines unilateral vs bilateral aldosterone excess based on cortisol-corrected aldosterone ratios from adrenal venous sampling, with ratio >4:1 indicating unilateral excess, ratio 3:1 suggestive of bilateral hypersecretion, and interpretation dependent on cosyntropin stimulation protocol used during sampling. Use when analyzing AVS results to guide surgical vs medical treatment decisions; triggers include 'AVS lateralization ratio', 'cosyntropin-stimulated AVS', 'aldosterone-to-cortisol ratio >4:1', and 'ratio 3:1 suggestive of bilateral disease'.

日本語の概要は準備中です。原文の説明を表示しています。

Helps distinguish unilateral from bilateral adrenal disease based on 18-oxocortisol levels, which are typically higher in aldosterone-producing adenoma than idiopathic adrenal hyperplasia. Use when evaluating 18-oxocortisol results during PA workup to guide subtype classification after a positive ARR.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests genetic counseling for patients with primary adrenal insufficiency (PAI) when a monogenic disorder is suspected. Use when PAI patient presents with early-onset disease, syndromic features, consanguinity, family history, or negative autoimmune antibodies.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends using the lowest tolerable hydrocortisone dose to potentially decrease risks of metabolic and cardiovascular disease in central adrenal insufficiency. Triggers include managing a patient with central adrenal insufficiency requiring glucocorticoid replacement.

日本語の概要は準備中です。原文の説明を表示しています。

Bedside prescribing reference for Bemdec (bempedoic acid / NEXLETOL) — indication check, dose, statin co-prescribing safety caps, monitoring plan, warnings for hyperuricemia and tendon rupture, and special population guidance. Use when a clinician asks "can I start bempedoic acid", "Bemdec indication", "is bempedoic acid safe with my statin", "patient on Nexletol has joint pain or high uric acid", "bempedoic acid in CKD or liver disease or pregnancy", or any prescribing or monitoring question about bempedoic acid.

日本語の概要は準備中です。原文の説明を表示しています。

Calculate and interpret the PREVENT-ASCVD risk score (10-year and 30-year) for primary prevention of atherosclerotic cardiovascular disease per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers inputs required, risk-category thresholds (low <3%, borderline 3–<5%, intermediate 5–<10%, high ≥10%), when to use the 30-year calculation (adults 30–59), and how PREVENT differs from the older Pooled Cohort Equations (lower risk estimates by 40–50%, race-agnostic). Use when a clinician asks what the 10-year ASCVD risk is, how to calculate PREVENT, PCE vs PREVENT, risk category for this patient, does my patient need a statin, 30-year risk calculation, primary prevention risk assessment. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Screen a child with obesity for red flags suggesting monogenic, syndromic, or secondary endocrine causes — distinguishing atypical from typical exogenous obesity. Trigger when a clinician asks whether obesity could be genetic or hormonal, suspects Prader-Willi syndrome, Cushing disease, hypothyroidism, ROHHAD, Bardet-Biedl syndrome, leptin deficiency, or craniopharyngioma, or when a child has early-onset severe obesity, short stature with obesity, hyperphagia, hypotonia, dysmorphic features, or developmental delay with weight gain.

日本語の概要は準備中です。原文の説明を表示しています。

Find the papers that answer a research query in Firecrawl's research paper index — a corpus of paper abstracts whose largest share is biomedical and life-science literature (PubMed, bioRxiv, medRxiv), alongside arXiv preprints in CS, physics, and math — using semantic search, semantic and structural expansion, and in-body verification. Use this skill for literature-finding and paper-retrieval tasks of any kind, including clinical, biomedical, drug, gene, disease, and other life-science questions, whether the answer is a single paper or a full multi-paper set. The index is reached only through the `firecrawl_research_*` MCP tools or the `firecrawl research` CLI subcommands. Calling `firecrawl_search` with its `categories` option set to `["research"]` is a different feature — it filters ordinary web search to research-affiliated websites (the list includes PubMed, bioRxiv, medRxiv, arXiv, and publisher sites) and returns page results from them, without querying the paper records in this index.

日本語の概要は準備中です。原文の説明を表示しています。

Ingeniero de Sistemas de Andru.ia. Diseña, redacta y despliega nuevas habilidades (skills) dentro del repositorio siguiendo el Estándar de Diamante.

日本語の概要は準備中です。原文の説明を表示しています。

Expert-level neuroscience covering neuronal physiology, synaptic transmission, brain regions and circuits, neuroplasticity, neurodegenerative diseases, and computational neuroscience.

日本語の概要は準備中です。原文の説明を表示しています。

中国药品权威数据库查询 — NMPA(国家药监局) + CDE(药品审评中心) + DrugBank(英文名/ATC) + PubChem(化学结构) 多源融合,提供(通用名 ↔ 商品名 ↔ 英文名 ↔ 适应症 ↔ NMPA 批文号 ↔ 上市日期)精确映射。Make sure to use this skill whenever the user mentions 药品名 / 通用名 / 商品名 / NMPA / 国药准字 / 药监局 / CDE / drug brand name / generic name / drug registry / pharmaceutical lookup / drug verification / 药物核验 / 商品名对应 / drug cross-check / drug authority lookup. 在任何 medical / market-sizing / clinical / disease-research 报告生成阶段,**所有药品提及必须先调 lookup_drug() 验证**,严禁 LLM 凭训练记忆拼凑通用名↔商品名↔英文名对应关系。LLM 训练截止后药企会更换商品名、新药持续上市,记忆完全不可信。Iron Law:lookup 返回 None → 调用方必须 raise UnverifiedDrugError,不允许 fallback 到记忆。免费公开数据源,跨平台:Claude Code / Codex / Gemini CLI 三端均可 auto-trigger,实现仅依赖 httpx + beautifulsoup4 标准生态,不绑定任何厂商 SDK。

日本語の概要は準備中です。原文の説明を表示しています。

Mid-run failure recovery for disease-market-sizing-orchestration. Inspects .cache/<slug>/ to determine which phase last completed and which phase to run next. Use when orchestration was interrupted and user wants to continue without restarting from phase 1.

日本語の概要は準備中です。原文の説明を表示しています。

Retrieves scientific papers from PubMed and creates plain-language research summaries. Use when users ask about medical research, scientific studies, clinical trials, disease treatments, or want to understand recent scientific literature on any biomedical topic.

日本語の概要は準備中です。原文の説明を表示しています。

Phase 4 Turn 2 of disease-market-sizing-orchestration (A6' upgrade). Audits compose output via Cite-or-Block strict — every anchor must reverse-resolve to an actual file in sources/, every fact claim must have an anchor. Returns verdict (ok/blocked) + violations list. Use AFTER cite-bound-content-generator (Turn 1), BEFORE report-bundle-builder (phase 5).

日本語の概要は準備中です。原文の説明を表示しています。

Phase 4 Turn 1 of disease-market-sizing-orchestration. Generates report HTML with mandatory citation anchors per fact claim. Reads contract + staging + sources/. Every drug/treatment/stat/recommendation MUST carry [pmid:.../guideline:.../nct:...] anchor that resolves to an actual file in sources/. NEVER hardcode drug names or numerical claims. Use AFTER evidence recall (phase 3), BEFORE content-verification-layer (Turn 2).

日本語の概要は準備中です。原文の説明を表示しています。

Phase 5 part of disease-market-sizing-orchestration. Injects consulting palette (navy/gold/blue) + base CSS + floating TOC + section dividers into raw report HTML. Validates token coverage ≥60% (warn) and floating TOC li ≥5 (block). Use AFTER content-verification passes, BEFORE report-bundle-builder build_all_deliverables.

日本語の概要は準備中です。原文の説明を表示しています。

Ingeniero de Sistemas de Andru.ia. Diseña, redacta y despliega nuevas habilidades (skills) dentro del repositorio siguiendo el Estándar de Diamante.

日本語の概要は準備中です。原文の説明を表示しています。

- Turn findings into a defensible intelligence product — BLUF key judgements, standardised estimative probability language, per-claim sourcing with timestamps and archived copies, separated observation, inference and assessment,… Use when writing an intelligence report, due-diligence memo, evidence pack or executive summary, or when asked to write up an investigation so it survives challenge

日本語の概要は準備中です。原文の説明を表示しています。

Ingeniero de Sistemas de Andru.ia. Diseña, redacta y despliega nuevas habilidades (skills) dentro del repositorio siguiendo el Estándar de Diamante.

日本語の概要は準備中です。原文の説明を表示しています。

Ingeniero de Sistemas de Andru.ia. Diseña, redacta y despliega nuevas habilidades (skills) dentro del repositorio siguiendo el Estándar de Diamante.

日本語の概要は準備中です。原文の説明を表示しています。

Artificial intelligence-driven transformative applications in disease ... — In cancer diagnostics, AI systems have achieved breakthrough performances

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes genetic variant effects on gene expression (RNA-seq), chromatin accessibility (DNASE), histone marks (ChIP), and transcription factors using the AlphaGenome API. Use when the user asks about non-coding variant effects, pathogenicity, clinical significance, disease associations, functional effects, gene expression changes, splicing disruption, or regulatory effects in promoters and enhancers. Also use for resolving biological terms to tissue/cell-type ontologies (UBERON/CL) or analyzing variants in chr:pos:ref>alt format.

日本語の概要は準備中です。原文の説明を表示しています。

Alternative Slowbar coffee intelligence — scientific analysis from seed to cup using First Principle + System Thinking. Covers: varieties, terroir, cultivation, disease diagnosis, processing, roasting physics/chemistry, extraction science, brewing, business strategy, storytelling. ALWAYS trigger for coffee-related questions requiring scientific depth. DO NOT trigger for simple recipes or general food questions. Style: science-driven, farmer-first, quality-obsessed.

日本語の概要は準備中です。原文の説明を表示しています。